Combat

Hydramethylnon (AC217300) is an insecticide primarily. Hydramethylnon is used for fire ants.

Pralidoxime Chloride (2-PAM chloride) is a useful agent in the treatment of organophosphate poisoning. Pralidoxime binds to organophosphate-inactivated acetylcholinesterase, used to combat poisoning by organophosphates or acetylcholinesterase inhibitors (nerve agents).

3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one shows antitumor activity in a human colon cancer cell line and may be used to combat thrombosis.

N-Acetylcarnosine (N-Acetyl-L-carnosine) is thought to be able to combat some of the effects of oxidative stress as it has anti-oxidant properties.

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound effective against various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its application potential lies in its ability to combat common antibiotic-resistant bacterial infections effectively. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may emerge as a novel antimicrobial agent in clinical inhibition.

Holanamine is a compound used to combat Leishmania donovani and has been identified as a non-competitive inhibitor of LdToP1B. Docking studies reveal that Holanamine exerts its antileishmanial effects through hydrogen bonds and hydrophobic interactions with the N-terminal and hinge regions of the LTop1B large subunit.

Tuberactinomycin compounds are essential components in the current combination of drugs used to combat Mycobacterium tuberculosis infections. These compounds target bacterial ribosomes and function by binding RNA and disrupting bacterial protein biosynthesis. Tuberactinomycin is produced by the actinomycete [Streptomyces puniceus], which binds RNA and inhibits protein synthesis in prokaryotes as well as certain forms of RNA splicing.

DHFR-IN-22 (Compound 8) is a DHFR (Dihydrofolate Reductase) inhibitor that falls under the category of 2,4-diaminopyrimidine compounds. It demonstrates significant inhibitory activity against isolated DHFR enzyme and major nontuberculous mycobacteria (NTM) species, specifically Mycobacterium avium and Mycobacterium abscessus. The compound has an IC50 of 1.1 nM and a MIC of 1.5 μg/mL for M. abscessus, and an IC50 of 6.3 nM and a MIC of 0.1 μg/mL for M. avium, while its IC50 for human DHFR is 2100 nM. DHFR-IN-22 may be promising for developing new strategies to combat NTM infections.

Insecticidal agent 21 (Compound 6) is an insecticide targeting Culex pipiens larvae with an LC50 of 0.4 μg/mL. It achieves multi-target neurotoxicity by inhibiting acetylcholinesterase (AChE) and simultaneously targeting other neural receptors, including nicotinic acetylcholine receptors (nAChR), voltage-gated sodium channels (VGSC), and γ-aminobutyric acid receptors (GABAAR). Insecticidal agent 21 shows potent insecticidal activity and can be utilized in the development of new insecticides to combat mosquito resistance to conventional agents.

Pks13-TE inhibitor 4 (compound 44) is a potent inhibitor from the thiazole series that effectively targets Pks13 to combat tuberculosis (TB) and addresses drug resistance.

Antitrypanosomal agent 20 (Compd 27) is a medication used to combat trypanosome infections, exhibiting an IC50 value of 0.75 μM against T. b. brucei.

SL antagonist 1 acts as a strigolactones antagonist, interacting strongly with SL receptor proteins to combat parasitic root weed invasion. It does not have any adverse effects on the germination of rice seeds or the growth and development of seedlings.

BAY38-7690, a hepatitis B virus inhibitor, may have potential for future therapeutic regimens to combat chronic HBV infection.

Isoliquiritin apioside, isolated from Glycyrrhizae radix rhizome, significantly decreases PMA-induced increases in MMP9 activities and suppresses PMA-induced activation of MAPK and NF-κB. Isoliquiritin apioside auppresseses invasiveness and angiogenesis o

anti-TNBC agent-1 is a highly effective compound specifically targeting and combating triple-negative breast cancer (TNBC), demonstrating remarkable potency against various breast cancer cell types with IC50 values ranging from 0.20 μM to 0.27 μM. Its mechanism of action involves inducing apoptosis in SUM-159 cells through the mitochondria pathway and causing G1 phase arrest in these cells.

Antistaphylococcal agent 3 is an antistaphylococcal therapeutic agent designed to combat Staphylococcus infections.

Tropatepine is an orally active antagonist of anticholinergic muscarinic. Tropatepine is an antiparkinsonian agent that can be used to combat against extrapyramidal syndrome caused by neuroleptic drugs [1][2].

Antiparasitic agent-10 (Compound 94) is a potent anti-parasitic agent with significant anti-schistosomal activity, particularly against adult Schistosoma mansoni, making it a promising candidate for Schistosomiasis research as a treatment option [1].

Anti gram-positive/negative bacteria agent 1 is an antibiotic conjugated with a synthetic MECAM-based siderophore, designed to combat both gram-positive and gram-negative bacteria.

Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that targets Zaire ebolavirus by binding to its surface glycoprotein, thereby preventing the virus's entry into host cells and demonstrating antiviral activity [1].

Atoltivimab (REGN3470), also known as maftivimab/odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1].

K11, an antimicrobial peptide, demonstrates activity against MDR/XDR K. pneumoniae isolates (MIC: 8-512 μg/mL) and inhibits bacterial biofilm formation. It also acts synergistically with various antibiotics (Chloramphenicol, Meropenem, Rifampicin, etc.) to combat drug-resistant K. pneumoniae and exhibits high thermal and wide pH stability [1].

Silevimig is a monoclonal antibody designed to combat RABV.

Neoviridogrisein I is utilized to combat Gram-positive bacteria and mycoplasma.